Get started

VIMTALABS

VIMTALABS: Parallel Channel & Flag BO, Chart of the WeekNSE:VIMTALABS Explodes 50%: From Parallel Channel Prison to Trendline Freedom Post Q1 FY26 Flag Breakout. Let's analyse it in the "Chart of the Week" As per the Latest SEBI Mandate, this isn't a Trading/Investment RECOMMENDATION nor for Educational Purposes; it is just for Informational purposes only. The chart data used is 3 Months old, as Showing Live Chart Data is not allowed according to the New SEBI Mandate. Disclaimer: "I am not a SEBI REGISTERED RESEARCH ANALYST AND INVESTMENT ADVISER." This analysis is intended solely for informational purposes and should not be interpreted as financial advice. It is advisable to consult a qualified financial advisor or conduct thorough research before making investment decisions. Price Action Analysis: - Current Price: ₹887.20 (as per chart) - 52-Week Range: ₹252 to ₹903 - Market Cap: ₹3,901 Crores - Recent Performance: Stock has shown exceptional momentum with 171% returns in the past year Volume Spread Analysis: - Breakout Volume: Exceptional volume spike during the August 2025 breakout - Volume Confirmation: Higher volumes on up-moves, lower on corrections - Accumulation Phase: Steady volume during the consolidation phase indicates smart money accumulation Chart Patterns: - Long-term Ascending Trendline: Yellow trendline acting as dynamic support since May 2024 - Parallel Channel Breakout: Stock consolidated in a 6-month parallel channel (₹400-550) from December 2024 to July 2025 - Flag and Pennant Formation: Classic continuation pattern post Q1 FY26 results - Volume Breakout: Massive volume surge accompanying the breakout, confirming genuine momentum Key Technical Levels: - Base Formation: ₹400-450 level established during Dec 2024 - Jul 2025 consolidation - Primary Support: ₹550-600 (previous resistance turned support) - Secondary Support: ₹500 (parallel channel upper boundary) - Immediate Resistance: ₹700-750 (psychological levels) - Final Resistance: ₹900-1000 Fundamental and Sectoral Backdrop: Company Overview: - Contract Research and Testing Organization serving biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, and medical device sectors Financial Performance: - Q1 FY26 Results: Net profit rose 53.83% to ₹19 Crore, sales increased 30.29% to ₹98 crore - Recent Quarter: EBITDA margins at 35.7% - Debt Position: The Company is almost debt-free Sector Dynamics: - CRO/CRAMS Sector: Strong tailwinds from global pharmaceutical outsourcing - Biologics Focus: Company expanding in high-growth biologics testing segment - Regulatory Compliance: Successfully completed US FDA GCP certification Other Highlights: - Consistent revenue growth across quarters - Strong margin expansion and operational efficiency - Debt-free balance sheet providing financial flexibility - Expanding service offerings in high-margin biologics - Beneficiary of the global pharma outsourcing trend Key Risk Factors: - High valuation metrics post recent rally - Dependence on the pharmaceutical sector cycles - Regulatory compliance requirements - Competition from larger CRO players Market Sentiment: - Recent 31% surge to hit a new 52-week high of ₹902, reflecting strong investor interest - Strong institutional interest evidenced by consistent buying - Positive analyst coverage post strong quarterly results Full Coverage on my Newsletter this Week Keep in the Watchlist and DOYR. NO RECO. For Buy/Sell. 📌Thank you for exploring my idea! I hope you found it valuable. 🙏FOLLOW for more 👍BOOST if you found it useful. ✍️COMMENT below with your views. Meanwhile, check out my other stock ideas on the right side until this trade is activated. I would love your feedback. As per the Latest SEBI Mandate, this isn't a Trading/Investment RECOMMENDATION nor for Educational Purposes, it is just for Informational purposes only. The chart data used is 3 Months old, as Showing Live Chart Data is not allowed according to the New SEBI Mandate. Disclaimer: "I am not a SEBI REGISTERED RESEARCH ANALYST AND INVESTMENT ADVISER." This analysis is intended solely for informational purposes and should not be interpreted as financial advice. It is advisable to consult a qualified financial advisor or conduct thorough research before making investment decisions.
NSE:VIMTALABSLong
by Karanshah137
3
We are in the 2nd phase in Nifty So the market moved exactly as we planned. NSE:NIFTY hit the 24750 target and then a Sell-on-Rise move dragged it lower into the close. This is why I mentioned yesterday that my stance would stay ‘Cautiously Bullish’. - Now, Nifty’s Pivot has shifted up to 24619. - PP stands at 0.16%. - Sellers’ volume is heavier than buyers by about 35 million. If we connect these points, if Nifty opens below Pivot and breaks the 24550 support, then we may see a quick drop towards 24450. If that level also gives way, then 24250 could come into play. But remember, individual stocks will still perform better. So stay stock-specific this and next week. Don’t chase breakouts, and avoid buying on MTF for now. This looks like a shakeout phase — needed to bring liquidity before Bulls take control again. Market trends always move in 3 phases: 1. Accumulation 2. Manipulation 3. Distribution Right now, we are in phase 2 (manipulation). The key is to spot where liquidity is building — that’s where you’ll find the exact bottom. NSE:BANKNIFTY is still holding support at 23575. If that breaks, 52680 can be expected in the coming days. Resistance sits at 54029. Sector-wise, construction and sugar look strong for tomorrow. My Today’s trades and performance: 1. NSE:MOBIKWIK – up 18.23% 2. NSE:VIMTALABS – up 16.83% Both hit upper circuits, so we booked full profit. Also fully booked $NSE:OLAELEC. That’s all for today. Take care. Have a profitable tomorrow.
NSE:NIFTYShort
by Trendxinc
1
Vimta LabsVimta Labs VLL is is in the business of contract research and testing in the fields of biologics, small molecules, agro -chemicals, food & beverages, electronics, clinical diagnostics, medical devices, home and personal care products, and environment testing On July 12th 2024, company approved the scheme of amalgamation of its Wholly Owned Subsidiary company viz. Emtac Laboratories Pvt. Ltd. with the Holding Company Market Cap: ₹ 2,603 Cr. Promoter holding: 36.7 % FII holding: 3.49 % DII holding: 1.42 % Public holding: 58.4 % Debt: ₹ 8.52 Cr. Debt 3Years back: ₹ 19.0 Cr. Looks good to buy and hold for the given Targets.
NSE:VIMTALABSLong
by isagar_chauhan_
1
Vimta Labs Limited - Breakout Setup, Move is ON...#VIMTALABS trading above Resistance of 952 Next Resistance is at 1214 Support is at 691 Here are previous charts: Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:VIMTALABSLong
by MandeepSinghKohli
Topline Growth + Op Leverage ComboChart is self explanatory. Vimta Labs is one of the well known food testing companies in India. As per Management guidance, 1. Company is targeting 500 Cr Revenue for 2026; and 2. Margin Expansion upwards of 30% At expected Revenue of 500 Cr and EBIT margins of 32% by 2026 - EBIT will be around 160 Cr and Net Profit 80 Cr at current NPM of 15% This equates to an EPS of 37 approximately. Now here's the tricky part - Finding a reasonable PE for this company. Ever since it got listed in 2020 at peak PE of 45, the parameter has been declining steadily and is ranging at 20 plus minus 5 now since mid 2021. At PE of 20, this would mean share price of 20 x 37 EPS = 740 by 2026 which is 25% CAGR approx. This is a very rough calculation, and things can go wrong, like they did when the company postponed the revenue target from 2025 to 2026. The price has formed bearish patterns at resistance levels, and it remains to be seen if it can give a breakout in the upside after a small traceback. Either way, it makes sense to study the business which has been able to 7x its EPS in 3 years, at 25% ROCE. Note : This is not an investment advice. This post is meant for educational purpose only. Kindly do your own due diligence before investing
NSE:VIMTALABSLong
by Aayush_Rungta
ADSC Mini Swing Call // Monday July 18th 2022 // NSE: VIMTALABSADSC Mini Swing Call // Monday July 18th 2022 // NSE: NSE:VIMTALABS // This is a swing trade call and not an intra-day trade. Please do not expect the stock to go up on the same day of posting or within a few sessions. Please follow the notes along with the posting before, during and after entering the trade // CMP / LTP: 398 TARGET: 418+ (15% Around) STOP LOSS: 388 (10% Max) Standard Notes: - Please follow the Stop Loss strictly and preferably on a daily closing basis. - Duration: 3-5Trading Days is suggested for all the mini swings and is an indicative period. - If SL / Target are not triggered and you still wish to hold the trade, this can be done as long as SL is followed or trailed. Disclosure: I may or may not have a position in this trade. Disclaimer: All the recommendations are subject to market conditions. Please trade at your own risks.
NSE:VIMTALABSLong
by Amit_Padishalwar